StocksMedium•17 November 2026•
1 min read
Merck Discontinues Nemtabrutinib Clinical Development Program for Blood Cancers
Key Facts
1Merck announced the discontinuation of the BELLWAVE clinical development program evaluating nemtabrutinib for hematologic malignancies.
Merck announced the discontinuation of the BELLWAVE clinical development program evaluating nemtabrutinib for hematologic malignancies. The company said in a statement via Business Wire that it decided to stop the development of the drug, also known as MK-1026, which was being tested as an oral BTK inhibitor for CLL, SLL, and other blood cancers.
The decision to discontinue the program followed an internal review of the investigational drug's clinical development path. Merck stock, trading under the ticker MRK, closed at $144.46 on November 16, 2026, with a session range between a low of $144.25 and a high of $149.23.